Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2024
-98.9%
Period ended Sep 29, 2024
Change on a year earlier
-1.1 pts
-97.8% in Q3 2023
History
7 quarters
Since Q4 2022
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2024 | Sep 29, 2024 | -98.9% | -1.1 pts | Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗ |
| Q2 2024 | Jun 30, 2024 | -39.7% | +7.7 pts | Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗ |
| Q1 2024 | Mar 31, 2024 | -96.7% | – | Form 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗ |
| Q4 2023 | Dec 31, 2023 | -95.2% | -50.2 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| Q3 2023 | Oct 1, 2023 | -97.8% | – | Form 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗ |
| Q2 2023 | Jul 2, 2023 | -47.4% | – | Form 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗ |
| Q4 2022 | Jan 1, 2023 | -45.0% | – | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%) (%), quarterly Q4 2022–Q3 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_intl_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.